SCHEMBL1473671

SCHEMBL1473671

Cc1ccc(C2=CC(=O)N(c3cccc(Br)c3)C2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.51
MAPT P10636 3/20 0.45
NPSR1 Q6W5P4 3/20 0.45
ALDH1A1 P00352 3/20 0.45
LMNA P02545 2/20 0.45
GAA P10253 2/20 0.45
RGS4 P49798 1/20 0.45
HTT P42858 1/20 0.45
CCR6 P51684 1/20 0.45
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
HSP90AA1 P07900 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
ATM Q13315 1/20 0.40
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471652 0.88 HSP90AA1 (0.54) MGLLMAPTNPSR1ALDH1A1LMNA
SCHEMBL1471735 0.87 MGLL (0.56) MGLLMAPTNPSR1ALDH1A1LMNA
SCHEMBL1471051 0.86 MAPT (0.49) MGLLMAPTNPSR1ALDH1A1LMNA
SCHEMBL1471536 0.83 RGS4 (0.57) MGLLMAPTNPSR1ALDH1A1LMNA
SCHEMBL1471071 0.82 GAA (0.48) MGLLMAPTNPSR1ALDH1A1LMNA
SCHEMBL1471680 0.81 MGLL (0.52) MGLLMAPTNPSR1ALDH1A1LMNA
SCHEMBL1471186 0.81 CYP1A2 (0.46) MAPTNPSR1ALDH1A1RGS4HTT
SCHEMBL1471845 0.79 HSP90AA1 (0.54) MGLLMAPTNPSR1ALDH1A1LMNA
SCHEMBL1473707 0.79 MGLL (0.47) MGLLMAPTNPSR1ALDH1A1LMNA
SCHEMBL1471125 0.79 HSP90AA1 (0.50) MGLLMAPTNPSR1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 MGLL 857/4885MAPT 1947/4885NPSR1 2341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.